Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 1/2017

Open Access 01-01-2017 | Original Article

Efficacy and safety of leuprorelin acetate 6-month depot, TAP-144-SR (6M), in combination with tamoxifen in postoperative, premenopausal patients with hormone receptor-positive breast cancer: a phase III, randomized, open-label, parallel-group comparative study

Authors: Junichi Kurebayashi, Tatsuya Toyama, Shuuji Sumino, Eri Miyajima, Tsukasa Fujimoto

Published in: Breast Cancer | Issue 1/2017

Login to get access

Abstract

Background

Leuprorelin acetate, a luteinizing hormone-releasing hormone agonist, is used worldwide in premenopausal women with hormone receptor-positive breast cancer. This study was conducted to assess the non-inferiority of the 6-month depot formulation, TAP-144-SR (6M) 22.5 mg to the 3-month depot formulation, TAP-144-SR (3M) 11.25 mg in postoperative, premenopausal patients with hormone receptor-positive breast cancer.

Methods

This was a 96-week phase III, randomized, open-label, parallel-group comparative study. All patients concomitantly received oral tamoxifen (20 mg daily). The primary endpoint was the suppression rate of serum estradiol (E2) to the menopausal level (≤30 pg/mL) from Week 4 through Week 48.

Results

In total, 167 patients were randomized to receive TAP-144-SR (6M) (n = 83) or TAP-144-SR (3M) (n = 84) and the E2 suppression rate was 97.6 and 96.4 %, respectively. The estimated between-group difference was 1.2 % (95 % confidence interval −5.2 to 7.8). The non-inferiority of TAP-144-SR (6M) to TAP-144-SR (3M) for E2 suppression was confirmed. As for safety, common adverse events were hot flush and injection site reactions including induration, pain, and erythema in both treatment groups, which were of ≤Grade 2 in severity and not serious. No significant between-group differences in safety profiles and tolerability were observed.

Conclusions

TAP-144-SR (6M) was not inferior to TAP-144-SR (3M) for its suppressive effect on serum E2. TAP-144-SR (6M) was also as well tolerated as TAP-144-SR (3M).
Literature
1.
Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol. 2001;19:3817–27.PubMed
2.
Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association Study. J Clin Oncol. 2002;20:4628–35.CrossRefPubMed
3.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–717.CrossRef
4.
Schmid P, Untch M, Kossé V, Bondar G, Vassiljev L, Tarutinov V, et al. Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study. J Clin Oncol. 2007;25:2509–15.CrossRefPubMed
5.
Klijn JG, Blamey RW, Baccardo F, Tominaga T, Duchateau L, Sylvester R. Combined tamoxifen and luteinizing hormone–releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol. 2001;19:343–53.PubMed
6.
Masuda N, Iwata H, Rai Y, Anan K, Takeuchi T, Kohno N, et al. Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer. Breast Cancer Res Treat. 2011;126:443–51.CrossRefPubMed
7.
The Japanese Breast Cancer Society Practice guideline for breast cancer in 2013 (in Japanese). Tokyo: Kanehara & Co., Ltd.; 2013.
8.
Christinat A, Di Lascio S, Pagani O. Hormonal therapies in young breast cancer patients: when, what and for how long? J Thorac Dis. 2013;5(Suppl 1):S36–46.PubMedPubMedCentral
9.
Regan MM, Pagani O, Fleming GF, Walley BA, Price KN, Rabaglio M, et al. Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials. Breast. 2013;22:1094–100.CrossRefPubMed
10.
Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009;20:1319–29.CrossRefPubMedPubMedCentral
11.
Shiavon G, Smith IE. Status of adjuvant endocrine therapy for breast cancer. Breast Cancer Res. 2014;16:206.CrossRef
12.
Komura E, Fujimoto T, Takabayashi N, Okamoto H, Akaza H. A phase II pharmacological study of leuprolide acetate 6-month depot, TAP-144-SR (6M), in treatment-naïve patients with prostatic cancer who received a single subcutaneous or intramuscular injection. Gan To Kagaku Ryoho. 2014;41:587–93 (in Japanese with English abstract).PubMed
13.
Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med. 1998;17:873–90.CrossRefPubMed
14.
Aso Y, Kameyama S, Niijima T, Ohmori H, Ohashi T, Murahashi I, et al. Clinical phase III study on TAP-144-SR, an LH–RH agonist depot formulation, in patients with prostatic cancer. Hinyokika Kiyo. 1991;37:305–20 (in Japanese with English abstract).PubMed
15.
Koiso K, Akaza H, Naito S, Usami M, Tsukamoto T, Shimazaki J, et al. Clinical effects of a 3-month formulation LH–RH agonist, TAP-144-SR (3M) in prostate cancer patients. Hinyokika Kiyo. 2002;48:781–95 (in Japanese with English abstract).PubMed
16.
Boccardo F, Rubagotti A, Amoroso D, Agostara B, Amadori D, Gallo L, et al. Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients. Cancer Chemother Pharmacol. 1999;43:461–6.CrossRefPubMed
17.
Suzuki K, Namiki M, Fujimoto T, Takabayashi N, Kudou K, Akaza H. Efficacy and safety of leuprorelin acetate 6-month depot in prostate cancer patients: a phase III, randomized, open-label, parallel-group, comparative study in Japan. Jpn J Clin Oncol. 2015;45:1168–74. doi:10.​1093/​jjco/​hyv149.PubMedPubMedCentral
18.
Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996;14:2738–46.PubMed
19.
Kiba T, Inamoto T, Nishimura T, Ueno M, Yanagihara K, Teramukai S, et al. The reversal of recurrence hazard rate between ER positive and negative breast cancer patients with axillary lymph node dissection (pathological stage I–III) 3 years after surgery. BMC Cancer. 2008;8:323.CrossRefPubMedPubMedCentral
20.
Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372:436–46.CrossRefPubMed
21.
Koc M, Polat P, Suma S. Effects of tamoxifen on pulmonary fibrosis after cobalt-60 radiotherapy in breast cancer patients. Radiother Oncol. 2002;64:171–5.CrossRefPubMed
22.
de Kam PJ, van Kuijk J, Lillin O, Post T, Thomsen T. The effect of therapeutic and supratherapeutic oral doses of nomegestrol acetate (NOMAC)/17β-estradiol (E2) on QTcF intervals in healthy women: results from a randomized, double-blind, placebo- and positive-controlled trial. Clin Drug Investig. 2014;34:413–20.CrossRefPubMed
23.
Shiba E, Yamashita H, Kurebayashi J, Noguchi S, Iwase H, Ohashi Y, et al. A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer. Breast Cancer. 2015. doi:10.​1007/​s12282-015-0593-z.PubMedPubMedCentral
24.
Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kässmann H, Piswanger-Sölkner JC, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 2008;9:840–9.CrossRefPubMed
Metadata
Title
Efficacy and safety of leuprorelin acetate 6-month depot, TAP-144-SR (6M), in combination with tamoxifen in postoperative, premenopausal patients with hormone receptor-positive breast cancer: a phase III, randomized, open-label, parallel-group comparative study
Authors
Junichi Kurebayashi
Tatsuya Toyama
Shuuji Sumino
Eri Miyajima
Tsukasa Fujimoto
Publication date
01-01-2017
Publisher
Springer Japan
Published in
Breast Cancer / Issue 1/2017
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-016-0691-6

Other articles of this Issue 1/2017

Breast Cancer 1/2017 Go to the issue

Original Article

Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer

Special Feature

The need for supplemental breast cancer screening modalities: a perspective of population-based breast cancer screening programs in Japan

Original Article

Impact of young age on local control after partial breast irradiation in Japanese patients with early stage breast cancer

Special Feature

Antitumor immunity and advances in cancer immunotherapy

Special Feature

Breast cancer screening with digital breast tomosynthesis

Original Article

Efficacy and safety of re-induction therapy with bevacizumab and paclitaxel for metastatic breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits